A	B	C	D	E	F	G	H
1	Main
2		Brand	Generic	Indication	MOA	Economics	Revenue	Disposition
3		Alimta	pemetrexed
4		Axiron
5		Baqsimi	glucagon
6		Basaglar, fka LY2963016	insulin glargine			BI
7		Cymbalta	duloxetine	Depression, Back Pain	SNRI
8		Cyramza
9		Effient	prasugrel	ACS	Platelet inhibitor	4568 JP
10		Emgality
11		Evista		Osteoporosis	SERM
12		Gemzar	gemcitibine
13		Glucagon
14		Humalog
15		Humulin
16		Jardiance
17		Livalo	pitavastatin	Hypercholesterolemia	Statin	Kowa
18		Olumiant, fka INCB28050	baricitinib	Rheumatoid Arthritis	JAK1/2	INCY
19		Permax					(2002-2007): 152, 165, 154, 117, 91, 87m
20		Qbrexza						Divested
21		Retevmo
22		Reyvow	lasmiditan	Migraine
23		Strattera	atomoxetine	ADHD
24		Symbyax		Bipolar
25		Taltz, fka LY2439821	ixekizumab	Rheumatoid Arthritis	IL-17 mab	1
26		Trajenta
27		Trulicity, fka LY2189265	dulaglutide	Type 2 Diabetes	GLP-1
28		Verzenio
29		Yentreve					(2004-2007): 4, 18, 25, 50m
30		Zyprexa	olanzapine	Schizophrenia, Bipolar	D2 antagonist		(2004-2007): 70, 54, 56, 50m
31		bebtelovimab	COVID-19
32		bamlanivimab/etesevimab	COVID-19
33
34
35
36
37
38
39		Brand	Generic	Indication	MOA	Economics	Phase	Admin
40			donanemab	Alzheimer's	a-beta mab
41			duloxetine	SUI
42			enzastaurin	NHL	PKC kinase
43		Survivin ASO		Cancer	Antisense	ISIS	II
44			edivoxetine	Depression	NRI
45			evacetrapib	Dyslipidemia	CETP	1	III
46		Inhaled Insulin
47		LY450139		Alzheimer's	Gamma Secretase
48		Naveglitazar
49		teplizumab
50			gemcitabine					oral
51		Factor Xa
52		ASAP
53			insulin peglispro				Abandoned
54		LY2624803
55			pomaglumetad
56			Ruboxistaurin
57			solanezumab	Alzheimer's	a-beta mab
58		LY2127399	tabalumab	SLE, RA, Multiple Myeloma, RRMS,	BAFF mab
59			tasisulam
60		LY2422347	Insomnia	5-HT2A